ArticleBiophysics reviews2025
The drug resistance feature of acute myeloid leukemia is related to the cell stiffness.
Article in Biophysics reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cholesterol Reprogramming in Acute Myeloid Leukemia: Integrating Tumor-Intrinsic Metabolism and Immune Crosstalk.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a hematologic cancer. Cytarabine-based chemotherapy is the primary treatment. However, drug resistance presents a significant challenge leading to treatment failure. Our study explores the underlying correlation between AML stiffness and its drug resistance feature. We employed microfluidic technology to measure AML cell deformability, demonstrating that drug-resistant cells exhibit increased stiffness compared to their drug-sensitive counterparts. Transcriptomic analysis revealed that enhanced stiffness in drug-resistant cells is associated with upregulated cytoskeletal protein expression and increased lipid metabolism, particularly the peroxisome proliferators-activated receptor (PPAR) signaling pathway. Mechanistically, we found that knocking down PLIN2 at the genetic level and increasing the cholesterol level promoted the deformation of drug-resistant cells, indicating that intracellular lipid levels are involved in the regulation of cell softness. Our findings suggest that AML cell stiffness could serve as a potential biomarker for drug resistance, providing new insights into the mechanisms underlying AML drug resistance and offering potential therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.